Brian Carr
About Brian Carr
Brian Carr is a seasoned entrepreneur and executive in the diagnostics industry, known for co-founding Versant Diagnostics and holding leadership roles in several other diagnostic companies.
Brian Carr Board Director Profile
Brian Carr serves as a Board Director, leveraging extensive experience across various medical and diagnostic companies. He has played a pivotal role in steering company strategies and providing governance oversight. His board roles span multiple prominent organizations, including Igenomix, Protypia, and SBA Communications Corp. His blend of leadership and industry expertise makes him a valuable asset to these organizations.
Co-Founder of Versant Diagnostics
Brian Carr co-founded Versant Diagnostics, contributing his expansive knowledge in diagnostics and executive leadership. Versant Diagnostics focuses on advancing diagnostic services to improve patient care. With his significant background in the field, Carr helps drive the company's mission and strategic initiatives.
Executive Roles in Diagnostic Laboratories
Brian Carr has held numerous executive roles in diagnostic laboratories. He served as Co-Founder, Chairman, and CEO of Regional Diagnostic Laboratories, where he guided the company's strategic direction. Similarly, at American Esoteric Laboratories, he was the Co-Founder, Chairman, and CEO, leading the organization to success in the diagnostic sector. His experience in these roles underscores his leadership capabilities and his impact on the industry.
Leadership at OralDNA Labs
As the Co-Founder and CEO of OralDNA Labs, Brian Carr was instrumental in establishing and expanding the company. OralDNA Labs focuses on developing diagnostic testing services for oral health. Carr's leadership helped advance the company's position in the healthcare market, contributing to its operational and strategic success.
AmeriPath Leadership
Brian Carr played a critical role at AmeriPath, serving as President and a member of the Board of Directors. AmeriPath is known for providing anatomic pathology, clinical pathology, and molecular diagnostic services. Under his leadership, AmeriPath expanded its services and strengthened its position in the healthcare industry.